Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program

Capricor Therapeutics announced that the US FDA has granted Orphan Drug Designation to Deramiocel, the company’s lead cell therapy candidate, for the potential treatment of Becker Muscular Dystrophy.